51
Participants
Start Date
September 4, 2018
Primary Completion Date
August 1, 2024
Study Completion Date
August 1, 2024
Autoantibody Reductive Therapy
TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
Treatment as Usual (TAU)
Antibiotics and steroids
University of Pittsburgh Medical Center, Pittsburgh
Thomas Jefferson University Medical Center, Philadelphia
Temple University Hospital, Philadelphia
University of Alabama at Birmingham, Birmingham
Dan Dilling, Chicago
Baylor University Medical Center, Houston
University of Utah Medical Center, Salt Lake City
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Brigham and Women's Hospital
OTHER
Temple University
OTHER
University of Pittsburgh
OTHER
University of Alabama at Birmingham
OTHER